SI2056807T1 - Zdravljenje vnetnih bolezni - Google Patents

Zdravljenje vnetnih bolezni

Info

Publication number: SI2056807T1
Authority: SI; Slovenia
Prior art keywords: treatment; inflammatory diseases; inflammatory; diseases
Prior art date: 2006-08-17

Application number

SI200731077T

Other languages

English (en)

Inventor

Betty C. Soliven

Original Assignee

University Of Chicago

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-17

Filing date

2007-08-17

Publication date

2012-12-31

2007-08-17 Application filed by University Of Chicago filed Critical University Of Chicago

2012-12-31 Publication of SI2056807T1 publication Critical patent/SI2056807T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Plural Heterocyclic Compounds (AREA)

SI200731077T 2006-08-17 2007-08-17 Zdravljenje vnetnih bolezni SI2056807T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US83822206P	2006-08-17	2006-08-17
PCT/US2007/018331 WO2008021532A2 (en)	2006-08-17	2007-08-17	Treatment of inflammatory diseases
EP07837041A EP2056807B1 (en)	2006-08-17	2007-08-17	Treatment of inflammatory diseases

Publications (1)

Publication Number	Publication Date
SI2056807T1 true SI2056807T1 (sl)	2012-12-31

Family

ID=38941849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI200731077T SI2056807T1 (sl)	2006-08-17	2007-08-17	Zdravljenje vnetnih bolezni

Country Status (16)

Country	Link
US (3)	US8258150B2 (sl)
EP (2)	EP2392320A1 (sl)
JP (3)	JP5216769B2 (sl)
CN (2)	CN101553216B (sl)
AU (1)	AU2007284337B2 (sl)
BR (1)	BRPI0715950A2 (sl)
CA (1)	CA2660880C (sl)
DK (1)	DK2056807T3 (sl)
ES (1)	ES2393631T3 (sl)
HR (1)	HRP20121034T1 (sl)
MX (1)	MX2009001788A (sl)
PL (1)	PL2056807T3 (sl)
PT (1)	PT2056807E (sl)
RU (1)	RU2440110C2 (sl)
SI (1)	SI2056807T1 (sl)
WO (1)	WO2008021532A2 (sl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8318812B2 (en)	2006-06-02	2012-11-27	The Ohio State University Research Foundation	Therapeutic agents for the treatment of lymphoid malignancies
SI2056807T1 (sl)	2006-08-17	2012-12-31	University Of Chicago	Zdravljenje vnetnih bolezni
US9149459B2 (en)	2008-07-23	2015-10-06	Novartis Ag	Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
CN102119028A (zh) *	2008-08-18	2011-07-06	诺瓦提斯公司	用于治疗脱髓鞘性周围神经病的氨基醇衍生物
RU2523281C2 (ru) *	2008-08-18	2014-07-20	Новартис Аг	Соединения для лечения периферических невропатий
EP2177521A1 (en)	2008-10-14	2010-04-21	Almirall, S.A.	New 2-Amidothiadiazole Derivatives
CA2739901A1 (en)	2008-10-17	2010-04-22	Akaal Pharma Pty Ltd	S1p receptors modulators
AU2009304598B2 (en)	2008-10-17	2015-01-29	Akaal Pharma Pty Ltd	S1P receptors modulators and their use thereof
EP2202232A1 (en)	2008-12-26	2010-06-30	Laboratorios Almirall, S.A.	1,2,4-oxadiazole derivatives and their therapeutic use
EP2210890A1 (en)	2009-01-19	2010-07-28	Almirall, S.A.	Oxadiazole derivatives as S1P1 receptor agonists
JP2012523458A (ja)	2009-04-13	2012-10-04	ザオハイオステートユニバーシティーリサーチファウンデーション	タンパク質ホスファターゼ２ａ活性化剤
US8362071B2 (en)	2009-04-17	2013-01-29	The Ohio State University Research Foundation	Antiadhesion agents
PT2467372T (pt)	2009-08-10	2016-08-23	Teva Pharma	Tratamento de distúrbios relacionados com bdnf usando laquinimod
EP2305660A1 (en)	2009-09-25	2011-04-06	Almirall, S.A.	New thiadiazole derivatives
EP2343287A1 (en)	2009-12-10	2011-07-13	Almirall, S.A.	New 2-aminothiadiazole derivatives
KR20160129093A (ko) *	2010-03-03	2016-11-08	테바 파마슈티컬 인더스트리즈 리미티드	라퀴니모드를 이용한 루푸스 신장염의 치료
EP2366702A1 (en)	2010-03-18	2011-09-21	Almirall, S.A.	New oxadiazole derivatives
EP2390252A1 (en)	2010-05-19	2011-11-30	Almirall, S.A.	New pyrazole derivatives
WO2012074960A2 (en) *	2010-11-29	2012-06-07	The Ohio State University Research Foundation	Fty720-derived anticancer agents
EP2766020A4 (en)	2011-10-12	2015-04-01	Teva Pharma	TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
JP2015505564A (ja)	2012-02-03	2015-02-23	テバファーマシューティカルインダストリーズリミティド	第一選択の抗ＴＮＥα療法に失敗したクローン病患者を治療するためのラキニモドの使用
RU2482842C1 (ru) *	2012-04-26	2013-05-27	Открытое акционерное общество "Новосибхимфарм"	Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
EP2708898A1 (de)	2012-09-14	2014-03-19	Sterna Biologicals GmbH & Co. Kg	Verfahren zur Diagnose eines molekularen Phänotyps eines an einer mit chronischen Entzündungen einhergehenden Erkrankung leidenden Patienten
HK1215210A1 (zh)	2012-11-07	2016-08-19	Teva Pharmaceutical Industries Ltd.	拉喹莫德胺盐
US9233927B2 (en)	2013-03-14	2016-01-12	Teva Pharmaceutical Industries, Ltd.	Crystals of laquinimod sodium and improved process for the manufacture thereof
CN103992985A (zh) *	2014-05-09	2014-08-20	上海大学	神经鞘氨醇在中枢神经系统中的作用
CN112237575A (zh) *	2020-11-09	2021-01-19	杭州端丽生物技术有限公司	芬戈莫德在防治鞘脂紊乱引起的神经退行性疾病中的医药用途
CN112924432A (zh) *	2021-04-08	2021-06-08	济宁市第一人民医院	一种血液真菌感染检测试剂盒及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5948820A (en) *	1994-08-22	1999-09-07	Yoshitomi Pharmaceutical Industries, Ltd.	Benzene compound and pharmaceutical use thereof
JPH1180026A (ja) *	1997-09-02	1999-03-23	Yoshitomi Pharmaceut Ind Ltd	新規免疫抑制剤、その使用方法およびその同定方法
EP1377554A1 (en) *	1999-06-16	2004-01-07	University Of Iowa Research Foundation	Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases
TWI335311B (en) *	2002-09-24	2011-01-01	Novartis Ag	Organic compounds
EP1663188B1 (en) *	2003-09-12	2016-08-10	Newron Sweden AB	Treatment of disorders of the nervous system
SI2056807T1 (sl) *	2006-08-17	2012-12-31	University Of Chicago	Zdravljenje vnetnih bolezni

2007
- 2007-08-17 SI SI200731077T patent/SI2056807T1/sl unknown
- 2007-08-17 EP EP11170326A patent/EP2392320A1/en not_active Withdrawn
- 2007-08-17 CN CN2007800344676A patent/CN101553216B/zh not_active Expired - Fee Related
- 2007-08-17 EP EP07837041A patent/EP2056807B1/en active Active
- 2007-08-17 HR HRP20121034TT patent/HRP20121034T1/hr unknown
- 2007-08-17 MX MX2009001788A patent/MX2009001788A/es active IP Right Grant
- 2007-08-17 AU AU2007284337A patent/AU2007284337B2/en not_active Ceased
- 2007-08-17 JP JP2009524698A patent/JP5216769B2/ja not_active Expired - Fee Related
- 2007-08-17 CA CA2660880A patent/CA2660880C/en not_active Expired - Fee Related
- 2007-08-17 WO PCT/US2007/018331 patent/WO2008021532A2/en not_active Ceased
- 2007-08-17 BR BRPI0715950-1A2A patent/BRPI0715950A2/pt not_active IP Right Cessation
- 2007-08-17 RU RU2009109418/15A patent/RU2440110C2/ru not_active IP Right Cessation
- 2007-08-17 US US12/377,736 patent/US8258150B2/en not_active Expired - Fee Related
- 2007-08-17 PT PT78370418T patent/PT2056807E/pt unknown
- 2007-08-17 DK DK07837041.8T patent/DK2056807T3/da active
- 2007-08-17 PL PL07837041T patent/PL2056807T3/pl unknown
- 2007-08-17 ES ES07837041T patent/ES2393631T3/es active Active
- 2007-08-17 CN CN201210024062.7A patent/CN102526736B/zh not_active Expired - Fee Related
2012
- 2012-08-06 US US13/567,590 patent/US9101576B2/en not_active Expired - Fee Related
2013
- 2013-03-04 JP JP2013041387A patent/JP2013144694A/ja active Pending
2015
- 2015-08-05 US US14/818,534 patent/US9370497B2/en not_active Expired - Fee Related
- 2015-08-17 JP JP2015160277A patent/JP2015221824A/ja active Pending

Also Published As

Publication number	Publication date
DK2056807T3 (da)	2012-10-22
RU2440110C2 (ru)	2012-01-20
US8258150B2 (en)	2012-09-04
WO2008021532A2 (en)	2008-02-21
ES2393631T3 (es)	2012-12-26
US20150335666A1 (en)	2015-11-26
CN102526736A (zh)	2012-07-04
CN101553216B (zh)	2012-03-21
AU2007284337B2 (en)	2012-07-19
US20130017190A1 (en)	2013-01-17
EP2056807B1 (en)	2012-09-26
WO2008021532A3 (en)	2008-05-29
CA2660880C (en)	2015-10-13
EP2392320A1 (en)	2011-12-07
CN102526736B (zh)	2016-01-20
US9370497B2 (en)	2016-06-21
HK1131047A1 (en)	2010-01-15
RU2009109418A (ru)	2010-09-27
PL2056807T3 (pl)	2013-02-28
US20100310547A1 (en)	2010-12-09
JP2015221824A (ja)	2015-12-10
CA2660880A1 (en)	2008-02-21
JP2013144694A (ja)	2013-07-25
BRPI0715950A2 (pt)	2013-07-30
US9101576B2 (en)	2015-08-11
MX2009001788A (es)	2009-09-23
JP5216769B2 (ja)	2013-06-19
AU2007284337A1 (en)	2008-02-21
CN101553216A (zh)	2009-10-07
JP2010500995A (ja)	2010-01-14
EP2056807A2 (en)	2009-05-13
HRP20121034T1 (hr)	2013-01-31
PT2056807E (pt)	2012-12-21

Publication	Publication Date	Title
SI2056807T1 (sl)	2012-12-31	Zdravljenje vnetnih bolezni
ZA200707591B (en)	2009-08-26	Dihyrothienopyrimidines for the treatment of inflammatory diseases
IL200368A0 (en)	2010-04-29	Treatment of diseases characterized by inflammation
ZA200710598B (en)	2009-08-26	Treatment of inflammatory conditions
SI2044111T1 (sl)	2015-02-27	Ciljanje komplementa faktorja H za zdravljenje bolezni
EP2004204A4 (en)	2010-06-02	TREATMENT OF NEURODEGENERATIVE DISEASES
PT2056863T (pt)	2017-07-04	Tratamento de doenças oculares
ZA200905364B (en)	2010-05-26	Treatment of diseases characterized by inflammation
ZA200806808B (en)	2009-10-28	Treatment of stressed patients
GB0700972D0 (en)	2007-02-28	Treatment of inflammatory disease
IL200091A (en)	2013-05-30	Kittensan to treat infectious diseases of the nail
PL2380585T3 (pl)	2015-11-30	Sposoby leczenia chorób autoimmunologicznych
GB0720976D0 (en)	2007-12-05	Treatment of inflammatory disease
EP1981343A4 (en)	2010-12-15	TREATMENT OF INFLAMMATORY DISEASES WITH TRIAZOL COMPOUNDS
GB0610183D0 (en)	2006-06-28	Treatment of neurodegenerative diseases
GB0723100D0 (en)	2008-01-02	Treatment of HFnEF
GB0526394D0 (en)	2006-02-08	Treatment of inflammatory diseases
GB0622136D0 (en)	2006-12-20	Treatment of gastrointestinal diseases
GB0623740D0 (en)	2007-01-10	Treatment of disease
ZA200904660B (en)	2010-04-28	Treatment of IL-1-Beta related diseases
GB0622137D0 (en)	2006-12-20	Treatment of gastrointestinal diseases
GB0611417D0 (en)	2006-07-19	Treatment of cndaria intoxication
GB0819446D0 (en)	2008-12-03	Treatment of inflammatory disorders
IL194261A0 (en)	2009-09-22	S-alkylisothiouronium derivatives for the treatment of inflammatory diseases
GB0411302D0 (en)	2004-06-23	Treatment of inflammatory diseases